Fig. 2From: Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapyIntensity-modulated radiotherapy plan of 2010 showing 95%-isodose coverage of bilateral cervical lymph nodes with simultaneous integrated boost (SIB) of 70Â Gy to the primary tumor and metastatic lymph nodesBack to article page